 NeuroBo Pharmaceuticals, Inc., a clinical-stage biotechnology company focused on multimodal, disease-modifying therapies for neurodegenerative diseases, today reported that the previously announced merger between NeuroBo Pharmaceuticals, Inc., NeuroBo and Gemphire Therapeutics Nasdaq: GEMP closed on December 31, 2019. The new combined company, known as NeuroBo Pharmaceuticals began trading on the Nasdaq exchange under the ticker NRBO on December 31, 2019. NeuroBo will focus on advancing the companys clinical-stage pipeline for neurodegenerative diseases. 